Page 84 - Demo

%u041f%u0435%u0440%u0432%u0430%u044f %u0414.%u0412.84 %u2116 4/2024 %u0421%u043e%u0432%u0440%u0435%u043c%u0435%u043d%u043d%u0430%u044f %u0442%u0435%u0440%u0430 %u043f%u0438%u044f %u043f%u0441%u0438%u0445%u0438%u0447%u0435%u0441%u043a%u0438%u0445 %u0440%u0430 %u0441%u0441%u0442%u0440%u043e%u0439%u0441%u0442%u0432 www.psypharma.ru26. Strassnig M., Rosenfeld A., Harvey P.D. Tardive dyskinesia: Motor system impairments, cognition and everyday functioning // CNS Spectrums. %u2013 2018. %u2013 Vol. 23 (6). %u2013 P%u0440. 370%u2013377. %u2013 https://doi.org/10.1017/S109285291700054226. Strassnig M., Rosenfeld A., Harvey P.D. Tardive dyskinesia: Motor system impairments, cognition and everyday functioning // CNS Spectrums. %u2013 2018. %u2013 Vol. 23 (6). %u2013 P%u0440. 370%u2013377. %u2013 https://doi.org/10.1017/S109285291700054227. Jackson R. et al. Assessment of the impact of tardive dyskinesia in clinical practice: consensus panel recommendations // Neuropsychiatric Disease and Treatment. %u2013 2021. %u2013 Vol. 17. %u2013 P%u0440. 1589%u20131597. %u2013 https://doi.org/10.2147/NDT.S31060527. Jackson R. et al. Assessment of the impact of tardive dyskinesia in clinical practice: consensus panel recommendations // Neuropsychiatric Disease and Treatment. %u2013 2021. %u2013 Vol. 17. %u2013 P%u0440. 1589%u20131597. %u2013 https://doi.org/10.2147/NDT.S31060528. Ondo W.G., Hanna P.A., Jankovic J. Tetrabenazine treatment for tardive dyskinesia: Assessment by randomized videotape protocol // American Journal of Psychiatry. %u2013 1999. %u2013 Vol. 156 (8). %u2013 P. 1279%u20131281. %u2013 https://doi.org/10.1176/ajp.156.8.127928. Ondo W.G., Hanna P.A., Jankovic J. Tetrabenazine treatment for tardive dyskinesia: Assessment by randomized videotape protocol // American Journal of Psychiatry. %u2013 1999. %u2013 Vol. 156 (8). %u2013 P. 1279%u20131281. %u2013 https://doi.org/10.1176/ajp.156.8.127929. Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: A doubleblind crossover study // Annals of Neurology. %u2013 1982. %u2013 Vol. 11 (1). %u2013 P%u0440. 41%u201347. %u2013 https://doi.org/10.1002/ana.41011010829. Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: A doubleblind crossover study // Annals of Neurology. %u2013 1982. %u2013 Vol. 11 (1). %u2013 P%u0440. 41%u201347. %u2013 https://doi.org/10.1002/ana.41011010830. Paleacu D., et al. Tetrabenazine treatment in movement disorders // Clinical Neuropharmacology. %u2013 2004. %u2013 Vol. 27 (5). %u2013 P%u0440. 230%u2013233. %u2013 https://doi.org/10.1097/01.wnf.0000136892.24629.9630. Paleacu D., et al. Tetrabenazine treatment in movement disorders // Clinical Neuropharmacology. %u2013 2004. %u2013 Vol. 27 (5). %u2013 P%u0440. 230%u2013233. %u2013 https://doi.org/10.1097/01.wnf.0000136892.24629.9631. Ricciardi L. et al. Treatment Recommendations for Tardive Dyskinesia // Canadian Journal of Psychiatry. %u2013 2019. %u2013 Vol. 64 (6). %u2013 P%u0440. 388%u2013399. %u2013 https://doi.org/10.1177/070674371982896831. Ricciardi L. et al. Treatment Recommendations for Tardive Dyskinesia // Canadian Journal of Psychiatry. %u2013 2019. %u2013 Vol. 64 (6). %u2013 P%u0440. 388%u2013399. %u2013 https://doi.org/10.1177/070674371982896832. Bernstein A.I., Stout K.A., Miller G.W. The vesicular monoamine transporter 2: An underexplored pharmacological target // Neurochemistry International. %u2013 2014. %u2013 Vol. 73. %u2013 P%u0440. 89%u201397. %u2013 https://doi.org/10.1016/j.neuint.2013.12.00332. Bernstein A.I., Stout K.A., Miller G.W. The vesicular monoamine transporter 2: An underexplored pharmacological target // Neurochemistry International. %u2013 2014. %u2013 Vol. 73. %u2013 P%u0440. 89%u201397. %u2013 https://doi.org/10.1016/j.neuint.2013.12.00333. Correll C.U., Carbon M. A new class of VMAT-2 inhibitors for tardive dyskinesia // TheLancet Psychiatry. %u2013 Vol. 4 (8). %u2013 P%u0440. 574%u2013575. %u2013 https://doi.org/10.1016/S2215-0366(17)30279-133. Correll C.U., Carbon M. A new class of VMAT-2 inhibitors for tardive dyskinesia // TheLancet Psychiatry. %u2013 Vol. 4 (8). %u2013 P%u0440. 574%u2013575. %u2013 https://doi.org/10.1016/S2215-0366(17)30279-134. Solmi M., et al. Treatment of tardive dyskinesia with VMAT-2 inhibitors: A systematic review and meta-analysis of randomized controlled trials // Drug Design, Development and Therapy. %u2013 2018. %u2013 Vol. 12. %u2013 P%u0440. 1215%u20131238. %u2013https://doi.org/10.2147/DDDT.S13320534. Solmi M., et al. Treatment of tardive dyskinesia with VMAT-2 inhibitors: A systematic review and meta-analysis of randomized controlled trials // Drug Design, Development and Therapy. %u2013 2018. %u2013 Vol. 12. %u2013 P%u0440. 1215%u20131238. %u2013https://doi.org/10.2147/DDDT.S13320535. Connolly A. et al. Meta-analysis and systematic review of vesicular monoamine transporter (VMAT-2) inhibitors in schizophrenia and psychosis // Psychopharmacology. %u2013 2024. %u2013 Vol. 241 (2). %u2013 P%u0440. 225%u2013241. %u2013 https://doi.org/10.1007/s00213-023-06488-335. Connolly A. et al. Meta-analysis and systematic review of vesicular monoamine transporter (VMAT-2) inhibitors in schizophrenia and psychosis // Psychopharmacology. %u2013 2024. %u2013 Vol. 241 (2). %u2013 P%u0440. 225%u2013241. %u2013 https://doi.org/10.1007/s00213-023-06488-3